Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Diagnostics, SelectHealth Sign Coverage Agreement for Thyroid Cancer Tests

NEW YORK— Interpace Diagnostics announced today that it has signed an agreement with SelectHealth/Intermountain Healthcare to offer its thyroid cancer detection assays to SelectHealth's 850,000 members in Utah and Idaho. 

As part of the agreement, physicians across SelectHealth's entire network can now use Interpace's ThyGeNext and ThyraMir assays to test questionable thyroid nodules for potential evidence of thyroid cancer.

In addition, Interpace said it will act as an in-network laboratory for these services to SelectHealth's members. 

"This continues the trend we have seen among other healthcare plans, both national and regional, to make our unique ThyGeNext/ThyraMir combination tests available to their members," Interpace CEO Jack Stover said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more